海外のバーキットリンパ腫治療のベスト医師 — ページ2

ヴォルフガング・ケストラー教授は、20年以上の経験を持つ、がん標的療法を専門とする著名なオーストリア人腫瘍内科医です。

• 乳がんおよび婦人科悪性腫瘍の専門家
• 高度なバイオマーカーを用いた個別化治療戦略を開発
• ウィーン医科大学准教授
• 主要な国際腫瘍学ジャーナルに多数の論文を発表

マイケル・シャピラ医師は、ソウラスキー医療センター（イヒロフ）の骨髄移植専門医であり、血液がん治療において豊富な経験を有しています。

• ヘブライ大学医学部卒業
• ハダッサ医療センターにて内科専門医資格取得
• ハダッサ医療センター骨髄移植科シニア医師

フレディ・アヴィヴ医師は、テルアビブの主要なスラスキー医療センターで、血液がんの治療において34 年以上の経験を有しています。

• 34 年にわたる腫瘍血液学への献身
• 悪性血液がんの専門家
• 著名なスラスキー医療センターで診療
• 最新の医療および生物学的治療における専門知識

イントララット病院にてバーキットリンパ腫を専門とする先駆的な血液専門医。タイの血液学の主要拠点であるタマサート大学で研修。

• リンパ腫症例に重点を置く認定血液専門医
• がん関連合併症の臨床リスク予測モデルを開発
• 複数の病院で看護学生の指導教官を務めた経験あり
• タイの血液学アカデミックコミュニティの積極的な参加者

ドロール・レビン医師は小児血液腫瘍学を専門とし、テルアビブのソラスキー医療センターでバーキットリンパ腫に注力しています。

• ソラスキー医療センター小児血液腫瘍科部長
• シュナイダー小児医療センターにて小児血液腫瘍学の専門研修を修了
• イスラエル小児血液腫瘍学会（ISPHO）会員
• イタリアのリッツォーリ整形外科研究所にて骨・軟部腫瘍学を研究

米国血液学会（American Society of Hematology）に認められた血液学の第一人者であるヤイール医師は、テルアビブのスラスキー医療センターで患者の治療にあたっています。

• テルアビブ医療センターでの血液学専門研修
• 臨床的卓越性に対する数々の研究助成金および賞の受賞者
• イスラエルおよび米国血液学会の活動会員
• リンパ球性を含む白血病研究に注力

アイドグド医師は、バクーのLiv Bona Dea病院にて、小児がんの早期発見に関するプレゼンテーションや議論を通じて多大な貢献をしてきました。

• 小児がんの早期発見を専門とする
• 小児腫瘍学の発展に向けた専門的な議論に参加
• バクーのLiv Bona Dea病院に勤務

アイハン・グルサン医師はバーキットリンパ腫を専門とし、デューク大学およびフレッド・ハッチンソンがん研究センターで幹細胞移植の高度なトレーニングを受けています。

• 血液学および幹細胞移植における_doctor_7070_年以上の経験
• ガジ大学成人幹細胞移植ユニットの創設者兼管理者
• トルコ血液学会会員
• 血液悪性腫瘍および移植成績に関する多数の論文を発表

フォックス医師はバーキットリンパ腫治療の専門家であり、ゾーリンゲンのメディカルセンターにて、革新的な治療法と血液腫瘍疾患に関する広範な研究を融合させています。

• 血液学・腫瘍学・緩和ケアクリニックの主任医師
• 化学療法、免疫療法、分子標的療法の専門家
• ドイツ腫瘍学・血液腫瘍学会の正会員
• がん治療の進歩に貢献する研究論文を多数発表

盧佩華博士は、米国および中国の両国でライセンスを取得した血液腫瘍内科の専門家であり、細胞免疫療法の先駆者です。北京医科大学を卒業後、米国で研鑽を積み、スタンフォード大学にて臨床フェローシップを修了、その後、米国国立衛生研究所（NIH）より二つの権威ある賞を受賞しました。中国における腫瘍浸潤リンパ球（CIK）細胞療法の最初の導入者の一人でもあります。2015年に帰国後は、CAR-T療法および血液がん治療の発展を牽引してきました。盧博士は、中国非公立医療機関協会血液病委員会委員長を含む10以上の医療関連組織において指導的役割を担っています。また、「医療管理賞」や「年間最優秀人民医師」など、国家レベルの表彰も受けています。
 

診療科：血液内科・リンパ腫＆骨髄腫センター

ドラッハ教授は腫瘍学を専門とし、特にバーキットリンパ腫に注力しており、コンフラテルニテ私立病院で専門的なコンサルテーションを提供しています。

• ウィーン大学内科第I病院の主任医師
• 多発性骨髄腫および悪性リンパ腫プログラムのディレクター
• オーストリア血液学・腫瘍学会理事会メンバー
• 120本以上の科学論文を発表

アクデニズ大学の腫瘍内科専門医 – アレムダル医師は、バーキットリンパ腫およびその他の血液がんを専門としています。

• 2006年にコジャエリ大学医学部を卒業
• 2018年に腫瘍内科の専門研修を修了
• アクデニズ大学病院で数年間勤務
• 現在はメディカルパーク・アンタルヤ病院コンプレックスで診療を行っている

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

ヒラ・マゲン博士は、シェバ医療センターのイスラエルを代表する血液腫瘍内科医です。多発性骨髄腫およびアミロイドーシスユニットを率いています。マゲン博士は、複雑な形質細胞疾患および高リスク骨髄腫の治療を専門としています。彼女は、革新的なポイント・オブ・ケアCAR-T療法プログラムの主任研究員です。彼女の研究は、高度な免疫療法を日常の臨床ケアにもたらしています。

• 100以上の科学論文および骨髄腫に関する画期的な研究を執筆。
• MDアンダーソンがんセンターおよびアーカンソー大学医学部でフェローシップを修了。
• CAR-T細胞療法および骨髄移植を実施。
• 2026年にNewsweek誌により世界第7位にランクされたシェバ医療センターに勤務。

アヴィハイ・シモニ医師は、シェバ医療センターの骨髄移植部門のディレクターです。複雑な血液がんの治療を専門としています。MDアンダーソンがんセンターで専門フェローシップを修了しました。シモニ医師は、高リスク患者に対して同種および自家移植を行っています。テルアビブ大学の教授であり、血液学のチェアマンを務めています。

• Forbes誌による2025年および2026年のイスラエルのベストドクターに選出。
• 細胞療法と移植に関する250以上の科学論文を執筆。
• 白血病、リンパ腫、多発性骨髄腫に対するCAR-T細胞療法を提供。
• Newsweek誌による世界トップ10病院に選ばれたシェバ医療センターに勤務。

エラド・ヤコビ博士は、イスラエルにおける小児CAR-T細胞療法のパイオニアです。シェバ医療センターの小児細胞療法センターを率いています。ヤコビ博士は、再発性および高リスクの小児白血病やリンパ腫の治療を専門としています。ジョンズ・ホプキンス大学および米国国立がん研究所でフェローシップを修了しました。

• シェバ医療センター先端バイオセラピーセンターの医療ディレクター。
• 小児血液腫瘍学に関する240以上の科学論文の著者。
• 小児科、小児血液学、腫瘍学の専門医認定を取得。
• CAR-T細胞療法と骨髄移植の統合を主導。

アブラハム・アヴィグドール博士は、シェバ医療センター血液学研究所の所長です。リンパ腫、CAR-T療法、複雑な血液がんの分野における世界的権威です。アヴィグドール博士は、イスラエル・リンパ腫ワーキンググループを設立しました。2026年にニューズウィーク誌によって世界第7位にランクされたクリニックの運営を支援しています。

• 血液腫瘍学および細胞療法に関する130以上の科学論文を執筆。
• リンパ腫および骨髄腫に対するCAR-T細胞療法の統合におけるパイオニア。
• 同種および自家骨髄移植プログラムを主導。
• イスラエル・リンパ腫研究グループの議長を務めた。